ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2018
CVR: 32323502
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2018. In 2018, the company reported a gross profit of EUR 7,218 and a net result of EUR 371,171 compared with EUR -479,755 the year before. That is a decrease of 97.2% compared with the year before. Equity in the 2018 report amounted to EUR 14,193,826. The solvency ratio was 99.9%.
- Gross Profit
- EUR 7,218
- Profit/Loss
- EUR 371,171
- Equity
- EUR 14,193,826
- Total Assets
- EUR 14,201,391
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 7K EUR | 371K EUR | 14.2M EUR | 0 |
| 2017 | - | 257K EUR | -480K EUR | 13.8M EUR | 0 |
| 2016 | - | 3.2M EUR | 3.4M EUR | 14.3M EUR | - |
| 2015 | - | 5.4M EUR | 5.6M EUR | 10.9M EUR | - |
| 2014 | - | 5.5M EUR | 5.8M EUR | 5.3M EUR | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2017. Gross profit came to DKK 257,277, and the net result was DKK -479,755.
About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
